Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Vasiliki Symeonidou

PhD, MSc, BSc

Postdoctoral Researcher

Acute Myeloid Leukaemia (AML) is the most aggressive blood cancer. Although progress has been made in treating young patient with AML, older patients diagnosed with this disease have a dismal prognosis. One of most common treatments for these patients is hypomethylating agents. Interestingly, even though hypomethylating agents have been used in the clinic for over a decade, we still lack fundamental understanding of their exact mechanisms of action. This gap in our knowledge prevents us from harvesting the true power of these agents. For my research I want to understand the mechanism of action and resistance of these agents. In addition to hypomethylating agents, I am also investigating the mechanisms of action and resistant of cereblon E3 ligase modulating drugs.


I joined the Vyas group in August 2020 as a Post-Doctoral Researcher. I moved to Oxford from Edinburgh where in 2020 I was awarded a Ph.D. from the University of Edinburgh. For my Ph.D. I studied a different but equally aggressive type of leukaemia, infant MLL-AF4-drive Acute Lymphoblastic Leukaemia.

Recent publications

More publications